Satellos Bioscience (NASDAQ:MSLE) Stock Rating Cut to Strong Sell at Zacks ResearchMarket Beat·Oct 23, 2026 at 10:00 AMMSLE-3.09%
Satellos Bioscience Participates in Guggenheim, Jefferies Healthcare ConferencesPUBT·Oct 21, 2026 at 11:06 AMMSLE-3.09%
Craig Hallum Begins Coverage on Satellos Bioscience (NASDAQ:MSLE)Market Beat·Oct 8, 2026 at 06:18 PMMSLE-3.09%
Satellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular DystrophyTip Ranks·Sep 30, 2026 at 11:28 AMMSLE-3.09%
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated "Moderate Buy" by Wall Street BrokeragesMarket Beat·Sep 28, 2026 at 08:14 AMMSLE-3.09%
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society CongressTip Ranks·Sep 15, 2026 at 11:30 AMMSLE-3.09%
Satellos Bioscience releases investor presentation on Duchenne muscular dystrophy programPUBT·Sep 10, 2026 at 09:07 PMMSLE-3.09%
